Limbix, maker of a prescription digital therapeutic aimed at treating depression in teens, scooped up $15 million in Series A2 funding, Mobi Health News reports.
The round was led by GSR Ventures, with participation from Digital Garage, Storm Ventures, Bixink, DN Capital, Korean Investment Partners, E& Investment, Gaingels, MVP, Operator Partners, Mana Ventures and Pacific Health Ventures.
Limbix announced its $9 million Series A in May 2020. The company said its A2 brings its total raise to $31 million.
Limbix is the creator of SparkRx, a prescription digital therapeutic that uses the principles of cognitive behavioral therapy to address depression in teens and young adults ages 13 to 22. It was released in October as part of the FDA’s relaxed regulatory requirements for digital health devices treating psychiatric disorders during the pandemic. Read more.
